Sagimet Stock: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026 (NASDAQ:SGMT)
· seekingalpha.com
Sagimet Biosciences is a catalyst-driven biotech, with value anchored to the upcoming U.S. Phase 3 denifanstat acne trial. Learn more on SGMT stock here.
Going into 2H26, the bull case for Sagimet Biosciences Inc. ( SGMT ) here is pretty clear. If they cleanly replicate their prior Phase 3 acne data in the U.S. w...